Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy
Crossref DOI link: https://doi.org/10.1186/s12885-017-3196-6
Published Online: 2017-03-23
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kim, Seung Tae
Lee, Jeeyun
Park, Se Hoon
Park, Joon Oh
Park, Young Suk
Kang, Won Ki
Lim, Ho Yeong
Funding for this research was provided by:
Samsung Medical Center (SMX1161251, GF01160111)
Ministry of Health and Welfare (HI14C3418)
